Every material Form 8-K Acumen Pharmaceuticals, Inc. has filed with the SEC since October 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acumen Pharmaceuticals said it will cut 52 full-time positions, about 90% of its current workforce, after deciding to stop developing sabirnetug and to evaluate strategic options. The company estimates about $7.75 million in severance and related cash costs, mostly recorded in the fourth quarter of 2026 and first quarter of 2027. It also repaid its K2 HealthVentures term loan in full on November 5, 2026, using cash on hand.
52 full-time positions cut, about 90% of current employees; restructuring began November 2, 2026 and is expected to be substantially complete by early 2027.
Estimated $7.75 million in cash costs for one-time severance and related expenses, with a significant portion recorded in Q4 2026 and Q1 2027.
Repaid a $23.3 million payoff amount on the K2 HealthVentures loan; the loan agreement terminated November 5, 2026 and related liens were released.
Additional outplacement, advisory and other costs tied to strategic options have not been estimated.
Acumen said the Phase 2 ALTITUDE-AD trial of sabirnetug did not meet its primary endpoint or key secondary endpoints in early Alzheimer's disease. The company plans to cease development of sabirnetug, cut costs and explore strategic options to maximize shareholder value, which removes its lead product candidate from development.
Primary endpoint (iADRS change at 18 months vs. placebo) missed at both 35 mg/kg and 50 mg/kg doses; CDR-SB and other key secondary endpoints not statistically significant
Amyloid plaque reduction was statistically significant at both doses at weeks 36 and 76; ARIA-E observed in about 10% of treated participants
Company plans to cease development, including the open-label extension, and evaluate strategic options including its Enhanced Brain Delivery program
Additional ALTITUDE-AD data expected in the coming weeks, which Acumen does not expect to change the trial's efficacy conclusions
Acumen Pharmaceuticals reported a third-quarter 2026 net loss of $25.4 million, narrower than $26.5 million a year earlier, and cash, cash equivalents and marketable securities of $78.6 million at September 30, 2026, down from $110.2 million at June 30, 2026. The company expects the cash to fund current clinical and operational activities into early 2027 and said topline results from its Phase 2 ALTITUDE-AD study are expected in November 2026.
Net loss was $25.4 million for the quarter ended September 30, 2026, versus $26.5 million a year earlier; loss per share was $0.35 versus $0.44.
Cash, cash equivalents and marketable securities were $78.6 million at September 30, 2026, versus $110.2 million at June 30, 2026, with runway expected into early 2027.
R&D expenses were $21.1 million versus $22.0 million a year earlier, mainly due to lower manufacturing, materials and CRO costs tied to ALTITUDE-AD.
Topline ALTITUDE-AD Phase 2 results for sabirnetug are expected in November 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acumen Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →